BioCentury | Apr 4, 2020
Product Development

Dealmaking in a pandemic: partnerships that could expedite COVID-19 countermeasures

COVID-19 may be putting the brakes on a broad swath of biopharma deals, but it has also triggered a host of partnerships for coronavirus countermeasures, pushing vaccine deals to their highest numbers in years. Many...
BioCentury | Apr 4, 2020
Product Development

Patient groups call out silver linings that could emerge from COVID-19 crisis

While chronic disease patients are navigating unprecedented challenges in access to drugs and care during the COVID-19 crisis, the silver lining is that it is forcing the hands of legislators, regulators and payers to increase...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Hakko, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Targeting the NCK1-WIPF1 interaction for enteropathogenic E. coli infection

DISEASE CATEGORY: Infectious disease INDICATION: Escherichia A peptide that blocks the interaction between NCK1 and WIPF1 could treat or protect against enteropathogenic E. coli infection. A key step of infection involves binding of the SH3.2...
BioCentury | Apr 1, 2020
Finance

Reversing course on IPO plans, iTeos draws $125M in private round with crossovers

With two programs having entered the clinic since the company’s series B round, iTeos chose to raise another large private round rather than seek to tap the public markets as it had expected, drawing a...
BioCentury | Apr 1, 2020
Emerging Company Profile

Aspen plans to drive iPS cell therapy into Parkinson’s patients with $70M A round

Aspen plans to bring its autologous iPS cell-based therapy into Parkinson’s disease patients while exploring the stem cell platform in new indications with a $70 million series A round led by OrbiMed Advisors. Existing investors...
BioCentury | Apr 1, 2020
Product Development

A primer on the new coronavirus and COVID-19: BioCentury editors in conversation

The rapid pace at which COVID-19 has transformed society has rippled through the biopharma industry, affecting not only companies’ business strategies, but their product pipelines and priorities as many of them adapt on the fly...
BioCentury | Mar 28, 2020
Product Development

COVID-19 crisis spurs innovation in rapid diagnostic technologies

Companies across the world are mobilizing to answer the call for diagnostic innovation brought on by the COVID-19 crisis. The advances made during this time could change the course of this and future outbreaks, but...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Thierry Bernard will become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen in 2015 as SVP of the molecular diagnostics business area, takes...
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
Items per page:
1 - 10 of 3273